Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: Efficacy, safety, and pharmacokinetics

Transplant Infectious Disease

Volumn 12, Issue 3, 2010, Pages 204-212

  Caldes A ^a   Gil Vernet, S ^a   Armendariz, Y ^a   Colom, H ^b   Pou, L ^c   Niubo J ^a   Llado L ^a   Torras, J ^a   Manito, N ^a   Rufi G ^a   Grinyo J M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cytomegalovirus disease; Cytomegalovirus infection; Ef ficacy; Ganciclovir; Pharmacokinetics; Safety; Solid organ transplantation; Valganciclovir

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIVIRUS AGENT;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; HYPERTRANSAMINASEMIA; LEUKOPENIA; LOW DRUG DOSE; MALE; NEUTROPENIA; PANCYTOPENIA; PERSISTENT VIRUS INFECTION; PHARMACOKINETICS; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; SHORT COURSE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; AGED; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; VIROLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

EID: 77953198161     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00481.x     Document Type: Article

References (36)

1. Tolkoff-Rubin NE, Rubin RH. Recent advances in the diagnosis and management of infection in the organ transplant recipient. Semin Nephrol 2000 20 (2) : 148 163.
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 357 (25) : 2601 2614.
3. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004 66 (1) : 329 337.
4. Yuen GJ, Drusano GL, Fletcher C, et al. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Antimicrob Agents Chemother 1995 39 (10) : 2350 2352.
5. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005 5 (2) : 218 227.
6. Pescovitz MD. Formulary considerations for drugs used to prevent cytomegalovirus disease. Am J Health Syst Pharm 2003 60 (23, Suppl 8) : S17 S21.
7. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001 61 (8) : 1153 1183.
8. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 44 (10) : 2811 2815.
9. Paya C, Humar A, Dominguez E, et al., Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4 (4) : 611 620.
10. Asberg A, Humar A, Rollag H, et al. VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007 7 (9) : 2106 2113.
11. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. Herpes 2004 11 (3) : 77 86.
12. Scott JC, Partovi N, Ensom MH. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Ther Drug Monit 2004 26 (1) : 68 77.
13. Turgeon N, Fishman JA, Doran M, et al. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transpl Infect Dis 2000 2 (1) : 2 10.
14. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004 17 (4) : 357 361.
15. Fellay J, Venetz JP, Aubert JD, et al. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Transplant Proc 2005 37 (2) : 949 951. (Pubitemid 40590754)
16. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005 79 (11) : 1477 1483.
17. Pescovitz MD. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transpl Infect Dis 1999 1 (Suppl 1) : 31 34.
18. Niubo J, Perez JL, Martinez-Lacasa JT, et al. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis 1996 24 (1) : 19 24.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 (1) : 31 41.
20. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 6 (2) : 262 274.
21. Niubo J, Perez JL, Carvajal A, et al. Effect of delayed processing of blood samples on performance of cytomegalovirus antigenemia assay. J Clin Microbiol 1994 32 (4) : 1119 1120.
22. Erice A, Gil-Roda C, Pérez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997 175 (5) : 1087 1092.
23. Erice A, Gil-Roda C, Perez JL, et al. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999 12 (2) : 286 297.
24. Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998 72 (7) : 5927 5936.
25. National Cancer Institute. Guidelines and tools for protocol development. National Cancer Institute., Rockville, MD 2006.
26. Pou LCF, Almirante B, Pascual C. A rapid liquid chromatographic (HPLC) method for determination of ganciclovir in serum. In : Galteau MM, Siest G, Henny J, eds. Biology Prospective. Comptes rendus du 8° colloque de Pont-a-Mousson., Paris, France: John Libbey Eurotext, 1993: 183-186.
27. Cope AV, Sabin C, Burroughs A, et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997 176 (6) : 1484 1490.
28. Pharsight Corp CU. WinNonlin analytical software. Professional version 3.3. Pharsight Corp, Mountain View, California.
29. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn)., NewYork, USA: Marcel Dekker, 1982: 84-111.
30. Caldes A, Colom H, Amendariz Y, et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother 2009 53 (11) : 4816 4824.
31. DuBois D, DuBois EF. Clinical calorimetry: tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Medicine 1916 17 (6.2) : 863 871.
32. Humar A, Siegal D, Moussa G, Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005 192 (7) : 1154 1157.
33. Sawyer MD, Mayoral JL, Gillingham KJ, et al. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. Arch Surg 1993 128 (2) : 165 169 discussion 170.
34. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002 186 (6) : 829 833.
35. Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000 181 (2) : 717 720.
36. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005 44 (5) : 495 507.